We have identified a gene polymorphism (K247R) within or close to the P-loop of BCR-ABL, which leads to the substitution of arginine for lysine. We investigated the allelic frequency of K247R by screening 157 CML patients and 213 healthy blood donors with conventional sequencing, restriction enzyme digest and single strand conformational polymorphism analysis, and found the arginine allele to be rare. Three out of five CML patients with the arginine allele of K247R failed to achieve a major cytogenetic response to imatinib, suggesting that the arginine allele may have reduced sensitivity. However, despite K247R's position in or near to the P-loop, biochemical and cellular assays of imatinib and dasatinib sensitivity showed no alteration compared to wild type. Clinicians should be aware that possession of the arginine allele of K247R does not reflect a mutation that necessitates a change in the therapeutic strategy, unless there are other signs of inadequate response to drug.
Introduction
Acquired resistance to imatinib is frequently associated with mutations in the kinase domain (KD) of BCR-ABL that interfere with drug binding. [1] [2] [3] [4] [5] KD mutations cluster in certain regions of the kinase and confer varying levels of drug resistance. 6 There is evidence that mutations within the ATP binding loop (P-loop) are associated with a poor prognosis compared to other mutation types, irrespective of their degree of imatinib resistance. 7, 8 While analyzing CML patients for KD mutations, we identified a single nucleotide polymorphism (K247R) at codon position 247 (numbering according to ABL type 1a 9 ) within or close to the P-loop of BCR-ABL, leading to arginine being substituted for lysine (hereafter referred to as BCR-ABL-K247R). Since the patients with BCR-ABL-K247R seemed to have suboptimal responses to imatinib, we hypothesized that the arginine allele may reduce sensitivity to imatinib.
Materials and methods
We identified all patients with CML, and available bone marrow white cells, who were treated with imatinib in the Department of Hematology at the University of Leipzig, Germany, in successive Novartis-sponsored trials. At the time of starting imatinib, patients had a median age of 53 years (range, 20-78 years), with a male to female ratio of 1:0.99. In all, 96 out of 157 patients were in chronic phase when they started imatinib (20 were newly diagnosed), 27 were in accelerated phase and 34 in blast crisis. Anonymous healthy blood donors from Northern England served as a control group (n ¼ 213). Informed consent was obtained according to the declaration of Helsinki from all patients and controls.
Sequence analysis of BCR-ABL and ABL in CML patients
RNA extracted from bone marrow white cells was reverse transcribed into cDNA as described. 10 BCR-ABL and ABL were specifically amplified by nested PCR, followed by automated sequencing. Primers' sequences are shown in Table 1 . BCR-ABL-K247R or ABL-K247R were detected by repeat sequencing and by AluI (New England BioLabs, Beverly, MA, USA) digestion of the PCR product, as the nucleotide exchange (AAG to AGG) eliminates the AluI recognition sequence.
Screening for ABL-K247R in healthy blood donors
Genomic DNA, extracted from peripheral blood, was screened for ABL-K247R by single strand conformational polymorphism (SSCP) analysis. 11 The primers used are shown in Table 1 . Positive results were confirmed by AluI digestion of the PCR product.
Generation of BaF3 cells expressing BCR-ABL-K247R and cell proliferation assays
The AatII/KpnI ABL-K247R kinase fragment cloned in pGEM7 (Promega, Madison, WI, USA) was generated by site-directed mutagenesis of the wild-type (wt) AatII/KpnI ABL kinase fragment. The ABL-K247R fragment was then subcloned into full-length p210 BCR-ABL in pGEM5, released as an EcoRI fragment and finally introduced into pSRa, as described.
12
Bosc23 cells 13 were transfected with pSRap210 BCR-ABL-K247R and retroviral supernatant was used to infect Ba/F3 cells, followed by selection of stable transfectants. 12 Ba/F3 cells expressing unmutated (hereafter referred to as WT) and T315I mutant p210 BCR-ABL have been described previously. 14 Comparable BCR-ABL expression was confirmed by immunoblot analysis. Exponentially growing parental Ba/F3 cells (supplemented with IL-3) and Ba/F3 cells expressing WT, p210
BCR-ABL-K247R or p210
BCR-ABL-T315I were plated in quadruplicate in the presence of imatinib (0-1 mM) and dasatinib (0-32 nM). Cell proliferation was measured in duplicate by methanethiosulfonate (MTS assay, Promega, Madison, WI, USA), as described. 12 Dasatinib was a gift from Bristol-Myers Squibb.
Immunoblotting
Lysates from the various cell lines, following 3 h of exposure to graded concentrations of imatinib (0-6.4 mM), were resolved by SDS-PAGE and transferred to Immobilon-P membranes (Millipore Corp., Bedford, MA, USA) in triplicate. Tyrosine-phosphorylated proteins were detected with the 4G10 antibody and BCR-ABL with CST 2862 (Cell Signaling Technology, Beverly, MA, USA).
ABL autophosphorylation and substrate phosphorylation assays
ABL-K247R was introduced into the ABL kinase domain (amino acids 220-498) by site-directed mutagenesis, the construct was cloned into pGEX KG, and Glutathione S-transferase (GST) fusion proteins were generated as described. 15 The WT and ABL-T315I constructs have been described. 16 Kinase autophosphorylation assays were performed in the presence of imatinib (0-5 mM) as described. 16 Equal protein loading was confirmed by immunoblotting using the Ab-2 antibody (Oncogene Science, Cambridge, MA, USA). The effects of imatinib (0-5 mM) and dasatinib (0-32 nM) on GST-Abl kinase activity were also examined in triplicate using an N-terminal biotin-linked peptide substrate (biotin-EAIYAAPFAKKK-amide; Upstate Biotechnology, Charlottesville, VA, USA), as described. 16 
Results and discussion
Since only cDNA was available from the CML patients, we sequenced both BCR-ABL-specific and ABL-specific PCR products. Amplification of ABL was successful in 157 patients and in 151 of these BCR-ABL could also be amplified. BCR-ABL-K247R (100%) was identified in PCR products from four patients, and their clinical characteristics are shown in Table 2 . ABL PCR products from these four patients were WT in three patients with 100% Ph þ metaphases, while one case possessed both the WT and ABL-K247R alleles. As the latter patient had a partial cytogenetic response at the time of the sample, this likely reflects amplification of paternal and maternal alleles from normal cells, while the template in the other three patients was derived from leukemic cells and thus reflects the nontranslocated WT ABL allele. ABL-K247R (50%) was also found in the ABL PCR product of one additional patient; the patient's clinical characteristics are shown in Table 2 . AluI digestion confirmed the sequencing results in all cases. Since there is no evidence of allele-specific variation in ABL expression, such as imprinting, 17 the allelic frequency in the CML population is 5/157 Â 2 ¼ 1.6%. After completing the analysis of the Leipzig patients, we identified one additional patient with BCR-ABL-K247R at OHSU (Table 2 ). CD3 þ and CD33 þ cells isolated at the time of complete cytogenetic response were negative for BCR-ABL by fluorescence in situ hybridization. Both BCR-ABLnegative cell populations were heterozygous for ABL-K247R, consistent with K247R being a polymorphism originating in WT ABL.
SSCP analysis for ABL-K247R of 213 Western European blood donors identified one heterozygous individual (allele frequency 1/213 Â 2 ¼ 0.2%). This result was confirmed by AluI restriction enzyme digestion. The frequency of ABL-K247R in controls was not significantly different from that of the CML patients (P ¼ 0.11, w 2 test with Yates' correction). Although different methodologies were used to estimate the allele frequencies in the patients with CML and in the normal control UK population, we believe that the results seen with these methods are comparable. SSCP analysis of genomic DNA gives a reliable estimate of allele frequency, whereas cDNA analysis may be influenced by allele-specific differences in gene expression; if anything using these two methods would tend to increase, not decrease the differences in allele frequencies Table 1 Primers used in this study between the two groups. While our work was in progress, Irving et al 18 reported that one out of 29 healthy controls was heterozygous for the arginine allele, and suspected that K247R may be a rare polymorphism, in accordance with our data.
While all five patients with BCR-ABL-K247R achieved a complete hematological response, three failed to achieve a major cytogenetic response to imatinib (median follow-up 15 months, range 6-24 months). Since K247R is localized within or close to the P-loop of BCR-ABL, a mutational hotspot in patients with acquired imatinib resistance, we hypothesized that the exchange of arginine for lysine might reduce sensitivity to imatinib. It should be noted that there is no complete consistency in the literature regarding the 5 0 boundary of the P-loop. Daley et al 9, 19 include residues as far 5 0 as M244, while homology considerations suggest that L248 represents the 5 0 end of the P-loop. 20 Whatever the correct definition of the 5 0 boundary, it is conceivable that an amino-acid exchange in position 247 may change the conformation of the P-loop and result in decreased drug binding. However, no significant differences between Ba/F3 cells expressing p210
BCR-ABL-WT and p210 BCR-ABL-K247R were found in proliferation assays, compared with positive control BaF/3 cells expressing p210
, which were resistant (Table 3 and Figure 1a ). Consistent with this, IC 50 values for inhibition of BCR-ABL tyrosine phosphorylation were similar in immunoblots of cellular lysates from Ba/F3 cells expressing p210 BCR-ABL-WT and p210
BCR-ABL-K247R and comparable results were seen with in vitro kinase assays using GST-Abl KD, with autophosphorylation or substrate phosphorylation as the end points (Table 3 and Figure 1b ). Proliferation assays carried out in the presence of dasatinib, an alternative SRC/ABL inhibitor, 21 were concordant with the results obtained with imatinib ( Table 3) .
The comparable imatinib sensitivity of p210 BCR-ABL-WT and p210 BCR-ABL-K247R is not entirely unexpected since the exchange of arginine for lysine is conservative. In contrast, the nonconservative L248R/V exchange, in immediate proximity to K247R, confers a high level of resistance. 19 Our data suggest that the failure of three out of five patients with BCR-ABL-K247R to achieve an MCR is likely to be a chance finding in a small cohort, but it is still possible that BCR-ABL-K247R may modulate disease biology over time, irrespective of imatinib sensitivity in in vitro assays. To ascertain this, it will be necessary to collect response data on more CML patients with BCR-ABL-K247R. Given that P-loop mutations have been associated with a very poor prognosis, 7, 8 clinicians should be aware that BCR-ABL-K247R does not reflect a mutation that necessitates a change in therapeutic strategy, unless there are other signs of inadequate response to treatment. 
